« Back
Home /
Partner: GenScript |Hölzel Diagnostika

GenScript

Genscript

GenScript - Gene synthesis and editing technology

GenScript is a leading biology contract research company focused on services for the early stages of drug discovery and research. The biotech company, founded in 2002, is headquartered in New Jersey, USA. GenScript offers a comprehensive portfolio of custom services that include gene synthesis, protein expression and purification, peptide synthesis, antibody production and cell line development. GenScript also produces catalog antibodies and kits as well as eStain and eBlot and offers support in assay development and screening, lead optimization and antibody drug development.

GenScript meets the need to develop pre-clinical drug candidates with competence and confidence in a time-efficient and cost-effective manner. With its history of success and experience, the most frequently cited biotech company in the world is an ideal and reliable innovation partner in drug research.

The Genscript Biotech Corporation is a global biotech company that applies its proprietary technology to a variety of areas from basic life sciences research to translational biomedical development, industrial synthetic products and cell therapy solutions. Leveraging its proprietary gene synthesis and other technology and expertise, the group has established four main platforms including (i) a leading platform for contract research organizations (CRO); (ii) a platform for Contract Development and Manufacturing Organizations (“CDMO”); (iii) a platform for industrial synthetic products; and (iv) an integrated global cell therapy platform. The CDMO platform provides comprehensive biologics discovery and development services to pharmaceutical, biotech, government and academic customers worldwide. The platform for industrial synthetic products develops products for food and feed processing, among other things. The cell therapy platform provides cell therapy solutions for patients with refractory diseases such as cancer and inflammatory diseases.

Due gene synthesis and editing technology, GenScript has made significant advances in its research and application in synthetic biology, mainly in its innovative therapy with chimeric antigen receptors (“CAR”), T cells (“CAR-T”) and industrial enzymes . As a result of many years of experience, GenScript developed many innovative technologies with which the position at the cutting edge of biological and medical research is maintained and strengthened. GenScript offers a wide range of reagents, optimized kits, and system solutions to help you advance your research.